一例新型冠状病毒肺炎患者抗凝药物治疗策略  

Anticoagulant drug therapy strategy for a patient with novel corona virus disease 2019

作　　者：邵丹[1] 毕铁琳[1] SHAO Dan;BI Tie-lin(China-Japan Union Hospital of Jilin University,Changchun 130033,China)

机构地区：[1]吉林大学中日联谊医院,吉林长春130033

出　　处：《实用药物与临床》2020年第10期933-936,共4页Practical Pharmacy and Clinical Remedies

摘　　要：目的探索新型冠状病毒肺炎(Corona virus disease 2019,COVID-19)患者的抗凝药物治疗策略。方法结合现有COVID-19文献报道及相关指南、共识,针对1例新型冠状病毒感染患者的凝血功能、肝功能变化及药物相互作用等,分析探讨抗凝药物治疗策略。结果2019新型冠状病毒(2019-nCoV)可能在患病初期即存在凝血功能紊乱,甚至易诱发弥散性血管内凝血(Disseminated intravascular coagulation,DIC),应该考虑COVID-19患者易出现肝功能不全,以及抗病毒药物洛匹那韦/利托那韦、达芦那韦/考比司他与华法林、利伐沙班、阿哌沙班、达比加群等抗凝药物均存在相互作用等,制定抗凝药物治疗策略。结论2019-nCoV易致机体高凝状态,应结合患者自身肝肾功能等情况及药物间相互作用,制定适宜的抗凝药物治疗策略,有利于改善预后。Objective To explore the anticoagulant drug treatment strategy for patients with novel corona virus disease 2019(COVID-19).Methods Based on the existing COVID-19 literature reports and related guidelines and consensus,in view of the changes of blood coagulation and liver function and drug interactions in a patient with novel corona virus infection,anticoagulant drug treatment strategies were analyzed and studied.Results The 2019 new coronavirus(2019-nCoV)could induce clotting disorders at the beginning,and even predisposed diffuse intravascular coagulation(disseminated intravascular coagulation,DIC).Anticoagulant treatment strategies should be established in the light of the fact that COVID-19 patients were prone to liver dysfunction,and that the antiviral drugs,lopinavir/ritonavir,darunavir/corbicil,interacted with warfarin,rivaroxaban,apixaban,dabigatine and other anticoagulants.Conclusion The 2019-nCoV is prone to hypercoagulability.Appropriate anticoagulant drug treatment strategies should be formulated based on the patients′liver and kidney functions and drug interactions,which is conducive to improving the prognosis.

关 键 词：新型冠状病毒肺炎 抗凝 临床药师 

分 类 号：R563.1[医药卫生—呼吸系统]